Hints and tips:
...Joseph Papa, Bausch & Lomb chief executive, said the deal “marks a tremendous milestone for Bausch & Lomb and an important step forward on the path to an independent company focused on eye health”....
...Joseph Papa, Bausch & Lomb chief executive, said the deal “marks a tremendous milestone for Bausch & Lomb and an important step forward on the path to an independent company focused on eye health.”...
...Bausch + Lomb is a storied household brand that made $182mn in net income on $3.8bn of revenue last year....
...It was the first company to raise more than $500mn in a US IPO since Bausch & Lomb’s rocky entry to public markets in May....
...Just two companies have raised more than $500mn in US IPOs this year — private equity group TPG in January and healthcare group Bausch & Lomb in May....
...June quarter, according to Refinitiv.The biggest was eyecare company Bausch & Lomb, which raised $630mm in May....
...Bausch & Lomb, the eyecare company that raised $630mn this week, appeared to fit the bill perfectly....
...Bausch & Lomb raised less money than initially planned and its shares have fallen more than a fifth from their offering price....
...The biggest was eyecare company Bausch & Lomb, which raised $630mn in May. Overall just $1.8bn has been raised from new issues in the past three months in North America....
...& Lomb....
...Eyecare company Bausch & Lomb provides a recent cautionary tale....
...Although some companies have delayed listing plans until the second half of the year, many businesses such as eyecare company Bausch & Lomb have continued to update paperwork with US securities regulators...
...IPO Shares in Bausch & Lomb, the eyecare unit of the company formerly known as Valeant Pharmaceuticals, begin trading today in New York after yesterday pricing its initial public offering below its target...
...& Lomb IPO prices below target amid volatile markets (FT) Brookfield taps banks to sell out of French towers firm TDF (Reuters) S4 Capital to publish delayed results (FT) Apollo profits beat expectations...
...Founded in 1853 by John Jacob Bausch in Rochester, New York, Bausch + Lomb grew to be a leader in the lucrative eyecare field....
...A former Bausch & Lomb executive, the 49-year-old built Allergan through a succession of deals that began in 2013 when the company he ran, then called Actavis, bought Ireland-headquartered Warner Chilcott...
...Using lenses created by Bausch & Lomb, and designed to protect pilots’ eyes when flying, aviator sunglasses were first marketed by the company under the Ray-Ban brand in 1937....
...But Valeant’s market capitalisation now stands at $4.9bn — well below the combined $20bn it paid for Bausch & Lomb and Salix — after the company’s value crumbled following an accounting scandal and fears...
...its remaining two units, which sell its Bausch & Lomb contact lens brand and its prescription drugs....
...But he questioned whether the company’s Bausch and Lomb eyecare division would grow as much as 7 per cent, given that the business had been flat in the third quarter and grew 2 per cent in the fourth quarter...
...Robert Bertolini, who currently serves on the boards of Charles River Laboratories and Actelion Pharmaceuticals and is the former president and CFO of Bausch & Lomb, will join the board of the New York-based...
...One person close to the group said it was considering adopting the moniker of its contact lens business, Bausch & Lomb....
...The company reported a litany of problems in virtually every part of its business, from safety problems at two of its factories to softer sales at Bausch & Lomb, its contact lens business....
...Allergan, a rival drugmaker that had been touted by analysts as a potential buyer for Salix and Bausch & Lomb, Valeant’s contact lens business, said it was not interested in acquiring either....
...In a separate regulatory filing on Monday, Valeant disclosed it had been subpoenaed by the US Department of Justice over payments between its Bausch & Lomb unit and medical professionals, adding to its legal...
International Edition